Tags

Type your tag names separated by a space and hit enter

Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model.
J Clin Virol. 2009 Apr; 44(4):268-71.JC

Abstract

BACKGROUND

It is accepted that oral poliovirus vaccine (OPV) can cause vaccine-associated paralytic poliomyelitis (VAPP) and that wild poliovirus infection can rarely present as transverse myelitis. It is therefore possible that OPV could cause transverse myelitis. We previously reported a case of transverse myelitis that developed in a 6-month-old boy, 7 days after receiving his second dose of OPV.

OBJECTIVES

Our aim was to test the virus from this patient with transverse myelitis for neurovirulence in a mouse model.

STUDY DESIGN

The TgPVR21 transgenic mouse line, which expresses the human poliovirus receptor CD155, was used to assess neurovirulence of the viruses tested. Neurovirulence was expressed as the PD(50), the dose of virus causing paralysis in 50% of the mice. Four type 3 polioviruses were tested: a prototype wild strain, a fully attenuated polio vaccine virus, a virus from a patient with VAPP and the virus from the patient with transverse myelitis.

RESULTS

The PD(50) for the wild poliovirus strain was 3.83 and for the fully attenuated vaccine strain, 7.63. The PD(50) for the two clinical isolates were between these values, > or = 4.96 for the poliovirus known to have caused VAPP and > or = 4.81 for the virus from the patient with transverse myelitis.

CONCLUSIONS

The report of an OPV strain from a transverse myelitis case being neurovirulent in an in vivo mouse model provides further evidence for a causal association between OPV and transverse myelitis.

Authors+Show Affiliations

Polio Reference Laboratory and Epidemiology Unit, Victorian Infectious Diseases Reference Laboratory, North Melbourne, Australia. bruce.thorley@mh.org.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19269246

Citation

Thorley, Bruce, et al. "Oral Poliovirus Vaccine Type 3 From a Patient With Transverse Myelitis Is Neurovirulent in a Transgenic Mouse Model." Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, vol. 44, no. 4, 2009, pp. 268-71.
Thorley B, Kelly H, Nishimura Y, et al. Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model. J Clin Virol. 2009;44(4):268-71.
Thorley, B., Kelly, H., Nishimura, Y., Yoon, Y. K., Brussen, K. A., Roberts, J., & Shimizu, H. (2009). Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model. Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology, 44(4), 268-71. https://doi.org/10.1016/j.jcv.2009.01.014
Thorley B, et al. Oral Poliovirus Vaccine Type 3 From a Patient With Transverse Myelitis Is Neurovirulent in a Transgenic Mouse Model. J Clin Virol. 2009;44(4):268-71. PubMed PMID: 19269246.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model. AU - Thorley,Bruce, AU - Kelly,Heath, AU - Nishimura,Yorihiro, AU - Yoon,Yeon Kyung, AU - Brussen,Kerri Anne, AU - Roberts,Jason, AU - Shimizu,Hiroyuki, Y1 - 2009/03/09/ PY - 2008/10/30/received PY - 2009/01/27/revised PY - 2009/01/28/accepted PY - 2009/3/10/entrez PY - 2009/3/10/pubmed PY - 2009/4/25/medline SP - 268 EP - 71 JF - Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology JO - J. Clin. Virol. VL - 44 IS - 4 N2 - BACKGROUND: It is accepted that oral poliovirus vaccine (OPV) can cause vaccine-associated paralytic poliomyelitis (VAPP) and that wild poliovirus infection can rarely present as transverse myelitis. It is therefore possible that OPV could cause transverse myelitis. We previously reported a case of transverse myelitis that developed in a 6-month-old boy, 7 days after receiving his second dose of OPV. OBJECTIVES: Our aim was to test the virus from this patient with transverse myelitis for neurovirulence in a mouse model. STUDY DESIGN: The TgPVR21 transgenic mouse line, which expresses the human poliovirus receptor CD155, was used to assess neurovirulence of the viruses tested. Neurovirulence was expressed as the PD(50), the dose of virus causing paralysis in 50% of the mice. Four type 3 polioviruses were tested: a prototype wild strain, a fully attenuated polio vaccine virus, a virus from a patient with VAPP and the virus from the patient with transverse myelitis. RESULTS: The PD(50) for the wild poliovirus strain was 3.83 and for the fully attenuated vaccine strain, 7.63. The PD(50) for the two clinical isolates were between these values, > or = 4.96 for the poliovirus known to have caused VAPP and > or = 4.81 for the virus from the patient with transverse myelitis. CONCLUSIONS: The report of an OPV strain from a transverse myelitis case being neurovirulent in an in vivo mouse model provides further evidence for a causal association between OPV and transverse myelitis. SN - 1873-5967 UR - https://www.unboundmedicine.com/medline/citation/19269246/Oral_poliovirus_vaccine_type_3_from_a_patient_with_transverse_myelitis_is_neurovirulent_in_a_transgenic_mouse_model_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1386-6532(09)00049-3 DB - PRIME DP - Unbound Medicine ER -